Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biodistribution, Safety, and Tolerability of Radiolabeled BIIB080 in Healthy Adults
NCT06454721Phase 1Completed
- Sponsor
- Biogen
- Start
- Jan 2025
- Primary completion
- Mar 2026
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of biib080 in Alzheimer's disease (AD), sponsored by Biogen. Primary endpoint: CNS Biodistribution of [89Zr]Zr-DFO-Diranersen Assessed as the Percentage of Dose Taken up by Each Region of Interest (ROI) at Day 8. Started Jan 2025; status: completed.
02
Drugs
biib080
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06454721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06454721.